CAR-T treatment

BIOLOGICAL2 trials

Sponsors

First Affiliated Hospital of Zhejiang University, The First Affiliated Hospital of Xiamen University

Conditions

Multiple MyelomaRelapsed/Refractory

Phase 2

B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

First Affiliated Hospital of Zhejiang UniversityMultiple Myeloma

Start: 2019-07-31End: 2022-12-31Target: 30Updated: 2019-06-04

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

RecruitingNCT06581640

The First Affiliated Hospital of Xiamen UniversityMultiple Myeloma, Relapsed/Refractory

Start: 2024-09-24End: 2028-12-31Target: 5Updated: 2024-09-25